MiR-135a induces resistance to gefitinib in NSCLC cells through RAC1 (a member of the Rho family of GTPases) and PI3K/Akt signaling pathways, whereas knockdown of miR-135a reverses the above resistance phenomenon (38). Here, PIK3CB is linked to non-small cell lung carcinoma.